BiotechTube
Home/Pipeline/Diagnostic Biomarker Validation (Lung Cancer)

Diagnostic Biomarker Validation (Lung Cancer)

Lung Cancer

Discovery/ValidationActive

Key Facts

Indication
Lung Cancer
Phase
Discovery/Validation
Status
Active
Company
Nordic-MUbio

About Nordic-MUbio

Nordic-MUbio is a specialized antibody reagent company formed through the merger and acquisition of several legacy brands, including Nordic (founded 1964) and MUbio (spun out in 2000). It has established itself as a niche player in research-use-only antibodies, with a growing pipeline in diagnostic biomarker validation for cancers. The company pursues growth through targeted acquisitions, academic partnerships, and leveraging its core competencies in antibody validation and technical support.

View full company profile

Therapeutic Areas

OncologyCardiovascularNeurobiology

Other Lung Cancer Drugs

DrugCompanyPhase
15dPMJ2Claradele PharmaceuticalsResearch
SUPLEXAAlloplex BiotherapeuticsPhase 1
Oncology Digital BiomarkersImvariaDevelopment
Aerosolized Platinum NanoparticlesHylaPharmPre-clinical
ENV105Kairos PharmaPhase 1
AI for Lung CancerInvenio ImagingResearch
Liposome ProgramNanoTech PharmaPreclinical/Phase 1/2
Dendritic Cell VaccineMegaNano BioTechPre-clinical
AI Biomarkers for Lung CancerBioAI HealthUnknown
PRDM2 TargetARIZ Precision MedicinePreclinical
ZEN-3694Zenith EpigeneticsProof-of-Concept
TEC-001 + KeytrudaTeclisonPhase 2